Journal Mobile Options
Table of Contents
Vol. 76, Suppl. 1, 2011
Issue release date: July 2011
Section title: Pediatric Meet the Professor
Horm Res Paediatr 2011;76(suppl 1):47–51
(DOI:10.1159/000329163)

Screening and Treatment of Dyslipidemias in Children and Adolescents

Daniels S.R.
Department of Pediatrics, University of Colorado, Denver School of Medicine, Aurora, Colo., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Pediatric Meet the Professor

Published online: 7/21/2011

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: http://www.karger.com/HRP

Abstract

Background/Aims: Cardiovascular disease is the most prominent cause of mortality worldwide. A key risk factor for atherosclerotic cardiovascular disease is the presence of dyslipidemia. Clinical approaches to evaluation and treatment of dyslipidemia in children and adolescents are presented. Methods: A review of published guidelines and presentation of illustrative cases. Results: Dyslipidemia is an important risk factor in early-stage atherosclerosis. Children and adolescents at high risk for dyslipidemia can be identified using a positive family history or the presence of other risk factors as a trigger. Once high-risk individuals are identified, primary treatment is lifestyle modification. In cases where low-density lipoprotein-cholesterol is high, pharmacologic intervention may be needed. Conclusions: Screening of appropriate children and adolescents for dyslipidemia and treating those at high risk are important for the long-term prevention of cardiovascular disease.


Article / Publication Details

First-Page Preview
Abstract of Pediatric Meet the Professor

Published online: 7/21/2011

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: http://www.karger.com/HRP


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.